Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapid sequence emergence of general anaesthesia
2024-516415-24-03Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam, flumazenil, naloxone, Sugammadex, rocuronium and 1 more in general anesthesia, sponsored by Radboud University Medical Center. Primary endpoint: Time to return of spontaneous breathing. Planned start Dec 2025; status: authorised.
02
Drugs
remimazolamflumazenilnaloxoneSugammadexrocuronium
03
Conditions
general anesthesia
Beyond the preview
Go deeper on 2024-516415-24-03.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516415-24-03.